# FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

> **NCT06865664** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (estimated)

## Conditions studied

- Rhabdomyosarcoma

## Interventions

- **DRUG:** fludarabine
- **DRUG:** cyclophosphamide
- **DRUG:** cetuximab
- **BIOLOGICAL:** FGFR4-CAR T Cells

## Key facts

- **NCT ID:** NCT06865664
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-22
- **Primary completion:** 2027-12-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06865664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06865664, "FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06865664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*